These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

340 related items for PubMed ID: 12552352

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
    De Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA, Bakker WH, Smith C, Pauwels S, Krenning EP.
    Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
    [Abstract] [Full Text] [Related]

  • 6. [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy.
    de Jong M, Breeman WA, Bernard BF, Bakker WH, Schaar M, van Gameren A, Bugaj JE, Erion J, Schmidt M, Srinivasan A, Krenning EP.
    Int J Cancer; 2001 Jun 01; 92(5):628-33. PubMed ID: 11340564
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Amifostine protects rat kidneys during peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate.
    Rolleman EJ, Forrer F, Bernard B, Bijster M, Vermeij M, Valkema R, Krenning EP, de Jong M.
    Eur J Nucl Med Mol Imaging; 2007 May 01; 34(5):763-771. PubMed ID: 17146655
    [Abstract] [Full Text] [Related]

  • 9. Differences in biodistribution between 99mTc-depreotide, 111In-DTPA-octreotide, and 177Lu-DOTA-Tyr3-octreotate in a small cell lung cancer animal model.
    Schmitt A, Bernhardt P, Nilsson O, Ahlman H, Kölby L, Forssell-Aronsson E.
    Cancer Biother Radiopharm; 2005 Apr 01; 20(2):231-6. PubMed ID: 15869461
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Radiation therapy of small cell lung cancer with 177Lu-DOTA-Tyr3-octreotate in an animal model.
    Schmitt A, Bernhardt P, Nilsson O, Ahlman H, Kölby L, Maecke HR, Forssell-Aronsson E.
    J Nucl Med; 2004 Sep 01; 45(9):1542-8. PubMed ID: 15347722
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors.
    Zhang J, Wang H, Jacobson O, Cheng Y, Niu G, Li F, Bai C, Zhu Z, Chen X.
    J Nucl Med; 2018 Nov 01; 59(11):1699-1705. PubMed ID: 29653971
    [Abstract] [Full Text] [Related]

  • 16. Long-term toxicity of [(177)Lu-DOTA (0),Tyr (3)]octreotate in rats.
    Rolleman EJ, Krenning EP, Bernard BF, de Visser M, Bijster M, Visser TJ, Vermeij M, Lindemans J, de Jong M.
    Eur J Nucl Med Mol Imaging; 2007 Feb 01; 34(2):219-27. PubMed ID: 17021812
    [Abstract] [Full Text] [Related]

  • 17. [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients.
    Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion JL, Schmidt MA, Bugaj JL, de Jong M, Krenning EP.
    Eur J Nucl Med; 2001 Sep 01; 28(9):1319-25. PubMed ID: 11585290
    [Abstract] [Full Text] [Related]

  • 18. Up-regulation of somatostatin receptor density on rat CA20948 tumors escaped from low dose [177Lu-DOTA0,Tyr3]octreotate therapy.
    Melis M, Forrer F, Capello A, Bijster M, Bernard BF, Reubi JC, Krenning EP, De Jong M.
    Q J Nucl Med Mol Imaging; 2007 Dec 01; 51(4):324-33. PubMed ID: 17923824
    [Abstract] [Full Text] [Related]

  • 19. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs.
    de Jong M, Breeman WA, Valkema R, Bernard BF, Krenning EP.
    J Nucl Med; 2005 Jan 01; 46 Suppl 1():13S-7S. PubMed ID: 15653647
    [Abstract] [Full Text] [Related]

  • 20. Diagnostic versus therapeutic doses of [(177)Lu-DOTA-Tyr(3)]-octreotate: uptake and dosimetry in somatostatin receptor-positive tumors and normal organs.
    Müller C, Forrer F, Bernard BF, Melis M, Konijnenberg M, Krenning EP, de Jong M.
    Cancer Biother Radiopharm; 2007 Feb 01; 22(1):151-9. PubMed ID: 17627424
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.